The Pharmacokinetics and Acceptability of Lopinavir/Ritonavir Minitab Sprinkles, Tablets, and Syrups in African HIV-Infected Children
The Pharmacokinetics and Acceptability of Lopinavir/Ritonavir Minitab Sprinkles, Tablets, and Syrups in African HIV-Infected Children
复制标题
DOI：
10.1097/qai.0000000000000135
复制
发表时间：
2014-06-01
影响因子：
3.6
通讯作者：
Gibb, Diana M.
中科院分区：
文献类型：
--
作者：
Musiime, Victor;Fillekes, Quirine;Gibb, Diana M.
背景：指南推荐洛匹那韦/利托那韦（LPV/r）分别作为年轻和年长HIV感染儿童的一线和二线治疗。方法：一项开放标签的比较生物利用度（随机交叉）研究比较了一种新的每日两次minitab喷洒制剂（40 mg/10 mg，Cipla Pharmaceuticals）与创新糖浆在3至10岁的艾滋病毒感染乌干达婴儿中的作用。
Background:Guidelines recommend lopinavir/ritonavir (LPV/r) as first- and second-line therapy for young and older HIV-infected children, respectively. Available formulations have limitations making their widespread use complex.Methods:An open-label comparative bioavailability (randomized crossover) study compared a novel twice-daily minitab sprinkle formulation (40 mg/10 mg, Cipla Pharmaceuticals) versus innovator syrup in HIV-infected Ugandan infants aged 3 to